Fig. 3
From: First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysis
One-way sensitivity analysis in patients with epithelioid histology. E Patients with epithelioid histology, NI Nivolumab plus ipilimumab, C Pemetrexed plus cisplatin/carboplatin, PFS Progression-free survival, PD Progressive disease, P Probability of second-line immunotherapy in chemotherapy group, WTP Willingness to pay, EV Average value, QALY Quality-adjusted life year